Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 340

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 340
---
, securities, cash, assets or any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event had the Preferred Warrant been exercised immediately prior to the applicable corporate event. During the three months ended March 31, 2025, 625Series A Preferred Warrants were exercised into 625shares of Series A Preferred Stock for gross proceeds of $ 500,000. During the three months ended March 31, 2024, no Series A Preferred Warrants were exercised into shares of Series A Preferred Stock. The Company’s Preferred Warrants were exercisable into Series A Preferred Stock, which had no cash redemption features that required liability treatment. The Company recorded the Preferred Warrants as equity. February 2025 Pre-funded Warrants and February 2025 Common Warrants On February 5, 2025, in connection with the February 2025 Offering (See Note 8), the Company sold (i) 15,000shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to 112,551shares of Common Stock, and (iii) Common Warrants to purchase up to 127,551shares of common stock, at a combined public offering price of $ 39.20per share and Warrant. During the three months ended March 31, 2025, 91,214shares of its common stock were issued following the exercise of certain Pre-Funded Warrants. As of March 31, 2025, The remaining 21,337Pre-Funded Warrants remain exercisable. F-26

Additionally, in connection with the February 2025 Offering, the Company
issued the February 2025 Common Warrants to purchase up to shares of common stock with an exercise price of $ per share,
which are immediately exercisable upon stockholder approval and have a term of exercise equal to following date of the initial
exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in
the event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price.

A summary of outstanding
warrants as of March 31, 2025 is as follows:

|                                         |     | Number of 
 Warrants  |         |     | Weighted 
 Average  
 Exercise 
 Price    |           |     | Weighted         
 Average          
 Remaining        
 Contractual Life 
 (in years)       |      |
|:----------------------------------------|